{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:34Z","timestamp":1792852714298,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a leading cause of morbidity and mortality worldwide. Traditional anticoagulants like heparin and vitamin K antagonists (VKAs) have shown efficacy in preventing and treating thrombosis but come with an inherent risk of bleeding due to their non-specific inhibition of multiple coagulation factors. Subsequent direct oral anticoagulants (DOACs), targeting specific factors such as Xa or thrombin, demonstrated improved safety profiles compared to VKAs, yet bleeding remains a concern. Accordingly, research is focused on developing anticoagulants with improved safety profiles. A safer class of anticoagulants would have broad appeal. The intrinsic pathway of coagulation, involving factor XI (FXI), has attracted attention as a potential target for safer anticoagulants. Preclinical studies and epidemiological data indicate that FXI deficiency or inhibition protects against thrombosis with minimal bleeding. Current research involves evaluating various FXI-directed strategies, and phase 2 studies have shown promising results in orthopedic surgery, atrial fibrillation, end-stage renal disease (ESRD), myocardial infarction, and ischemic stroke. Several agents, such as antisense oligonucleotides, monoclonal antibodies, small synthetic molecules, natural peptides, and aptamers, have been developed to inhibit FXI at different stages, offering potentially safer alternatives to traditional anticoagulants. However, the optimal balance between preventing thrombosis and the risk of bleeding associated with FXI inhibitors requires validation through extensive phase 3 clinical trials using definite clinical endpoints. Several of such trials are currently underway or planned to define the role of FXI inhibitors in clinical practice and determine the most suitable FXI inhibitor for each specific indication. The current review highlights\u00a0the rationale behind developing FXI inhibitors, presenting the most advanced agents in development, summarizing completed clinical trials, and discussing ongoing research efforts.<\/jats:p>","DOI":"10.1007\/s11239-024-02972-5","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T01:03:15Z","timestamp":1713229395000},"page":"1315-1328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Factor XI: structure, function and therapeutic inhibition"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0388-3174","authenticated-orcid":false,"given":"Ahmed E.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-7707","authenticated-orcid":false,"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"2972_CR1","doi-asserted-by":"crossref","unstructured":"Bouma BN, Griffin JH (1977) Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252:6432\u20136437","DOI":"10.1016\/S0021-9258(17)39977-5"},{"key":"2972_CR2","doi-asserted-by":"publisher","first-page":"25139","DOI":"10.1074\/jbc.M001890200","volume":"275","author":"DH Ho","year":"2000","unstructured":"Ho DH, Badellino K, Baglia FA, Sun M-F, Zhao M-M, Gailani D, Walsh PN (2000) The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. J Biol Chem 275:25139\u201325145","journal-title":"J Biol Chem"},{"key":"2972_CR3","doi-asserted-by":"publisher","first-page":"29023","DOI":"10.1074\/jbc.271.46.29023","volume":"271","author":"Y Sun","year":"1996","unstructured":"Sun Y, Gailani D (1996) Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 271:29023\u201329028","journal-title":"J Biol Chem"},{"key":"2972_CR4","doi-asserted-by":"publisher","first-page":"12886","DOI":"10.1021\/bi701501k","volume":"46","author":"FA Baglia","year":"2007","unstructured":"Baglia FA, Walsh PN (2007) Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor-XI activation by thrombin. Biochemistry 46:12886\u201312887","journal-title":"Biochemistry"},{"key":"2972_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nsmb1095","volume":"13","author":"E Papagrigoriou","year":"2006","unstructured":"Papagrigoriou E, McEwan PA, Walsh PN, Emsley J (2006) Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 13:557\u2013558","journal-title":"Nat Struct Mol Biol"},{"key":"2972_CR6","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1021\/bi00222a008","volume":"30","author":"BA McMullen","year":"1991","unstructured":"McMullen BA, Fujikawa K, Davie EW (1991) Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry 30:2056\u20132060. https:\/\/doi.org\/10.1021\/bi00222a008","journal-title":"Biochemistry"},{"key":"2972_CR7","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","volume":"4","author":"X Wang","year":"2006","unstructured":"Wang X, Smith P, Hsu MY, Gailani D, Schumacher W, Ogletree M, Seiffert D (2006) Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 4:1982\u20131988","journal-title":"J Thromb Haemost"},{"key":"2972_CR8","doi-asserted-by":"publisher","first-page":"18655","DOI":"10.1074\/jbc.M802275200","volume":"283","author":"W Wu","year":"2008","unstructured":"Wu W, Sinha D, Shikov S, Yip CK, Walz T, Billings PC, Lear JD, Walsh PN (2008) Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa. J Biol Chem 283:18655\u201318664","journal-title":"J Biol Chem"},{"key":"2972_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI (2021) Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol 78:625\u2013631","journal-title":"J Am Coll Cardiol"},{"key":"2972_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11239-011-0578-5","volume":"32","author":"RS Woodruff","year":"2011","unstructured":"Woodruff RS, Sullenger B, Becker RC (2011) The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis 32:9\u201320. https:\/\/doi.org\/10.1007\/s11239-011-0578-5","journal-title":"J Thromb Thrombolysis"},{"key":"2972_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, Legnazzi M, Mauro MS, Mazzone PM, Occhipinti G (2023) Pharmacology and clinical development of factor XI inhibitors. Circulation 147:897\u2013913","journal-title":"Circulation"},{"key":"2972_CR12","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","volume":"123","author":"JW Yau","year":"2014","unstructured":"Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenko AS, Monia BP, Weitz JI (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123:2102\u20132107","journal-title":"Blood"},{"key":"2972_CR13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM200003093421004","volume":"342","author":"JC Meijers","year":"2000","unstructured":"Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR (2000) High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342:696\u2013701","journal-title":"N Engl J Med"},{"key":"2972_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1160\/TH10-05-0307","volume":"105","author":"O Salomon","year":"2011","unstructured":"Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U (2011) Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 105:269\u2013273","journal-title":"Thromb Haemost"},{"key":"2972_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/ATVBAHA.109.197178","volume":"30","author":"WA Schumacher","year":"2010","unstructured":"Schumacher WA, Luettgen JM, Quan ML, Seiffert DA (2010) Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 30:388\u2013392","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2972_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1084\/jem.20052458","volume":"203","author":"C Kleinschnitz","year":"2006","unstructured":"Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer H-U, Burfeind P, Renn\u00e9 C, Gailani D, Nieswandt B, Renn\u00e9 T (2006) Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203:513\u2013518","journal-title":"J Exp Med"},{"key":"2972_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.thromres.2009.12.013","volume":"125","author":"M Takahashi","year":"2010","unstructured":"Takahashi M, Yamashita A, Moriguchi-Goto S, Sugita C, Matsumoto T, Matsuda S, Sato Y, Kitazawa T, Hattori K, Shima M (2010) Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and\/or blood stasis. Thromb Res 125:464\u2013470","journal-title":"Thromb Res"},{"key":"2972_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cts.13148","volume":"15","author":"V Perera","year":"2022","unstructured":"Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D (2022) First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci 15:330\u2013342","journal-title":"Clin Transl Sci"},{"key":"2972_CR19","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/jth.15439","volume":"19","author":"D Thomas","year":"2021","unstructured":"Thomas D, Kanefendt F, Schwers S, Unger S, Yassen A, Boxnick S (2021) First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost 19:2407\u20132416","journal-title":"J Thromb Haemost"},{"key":"2972_CR20","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1111\/bcp.15230","volume":"88","author":"D Kubitza","year":"2022","unstructured":"Kubitza D, Heckmann M, Distler J, Koechel A, Schwers S, Kanefendt F (2022) Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study. Br J Clin Pharmacol 88:3447\u20133462","journal-title":"Br J Clin Pharmacol"},{"key":"2972_CR21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Gailani D, Weitz JI (2015) Factor XI antisense oligonucleotide for venous thrombosis. N Engl J Med 372:1672\u20131672","journal-title":"N Engl J Med"},{"key":"2972_CR22","doi-asserted-by":"crossref","unstructured":"Chan NC, Weitz JI (2019) AB023, a novel antibody that binds factor XI and blocks its activation by factor XIIa. Arterioscler Thromb Vasc Biol 39:533\u2013535","DOI":"10.1161\/ATVBAHA.119.312459"},{"key":"2972_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","volume":"39","author":"CU Lorentz","year":"2019","unstructured":"Lorentz CU, Verbout NG, Wallisch M, Hagen MW, Shatzel JJ, Olson SR, Puy C, Hinds MT, McCarty OJ, Gailani D (2019) Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler Thromb Vasc Biol 39:799\u2013809","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2972_CR24","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/jth.15744","volume":"20","author":"B Nowotny","year":"2022","unstructured":"Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S (2022) First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men. J Thromb Haemost 20:1684\u20131695. https:\/\/doi.org\/10.1111\/jth.15744","journal-title":"J Thromb Haemost"},{"key":"2972_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1182\/blood.2019000919","volume":"135","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Chan NC (2020) Novel antithrombotic strategies for treatment of venous thromboembolism. Blood 135:351\u2013359","journal-title":"Blood"},{"key":"2972_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jth.15577","volume":"20","author":"BA Yi","year":"2022","unstructured":"Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M (2022) Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa. J Thromb Haemost 20:307\u2013315","journal-title":"J Thromb Haemost"},{"key":"2972_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2022","unstructured":"Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Rosie ZY, Wang Y, Geary RS, Weitz J, Bhanot S (2022) Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep 7:200\u2013209","journal-title":"Kidney Int Rep"},{"key":"2972_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, B\u00fcller HR, Raskob GE, Weitz JI (2021) Abelacimab for prevention of venous thromboembolism. N Engl J Med 385:609\u2013617","journal-title":"N Engl J Med"},{"key":"2972_CR29","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.122.061132","volume":"146","author":"JI Weitz","year":"2022","unstructured":"Weitz JI, Eikelboom JW (2022) What is the future of factor XI inhibitors? Circulation 146:1899\u20131902","journal-title":"Circulation"},{"key":"2972_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399:1383\u20131390","journal-title":"Lancet"},{"key":"2972_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas J-L (2022) Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 400:997\u20131007","journal-title":"Lancet"},{"key":"2972_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","volume":"146","author":"SV Rao","year":"2022","unstructured":"Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L (2022) A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 146:1196\u20131206","journal-title":"Circulation"},{"key":"2972_CR33","doi-asserted-by":"publisher","first-page":"106742","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106742","volume":"31","author":"M Sharma","year":"2022","unstructured":"Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A (2022) Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 31:106742","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2972_CR34","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","volume":"116","author":"H Zhang","year":"2010","unstructured":"Zhang H, L\u00f6wenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES (2010) Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 116:4684\u20134692","journal-title":"Blood"},{"key":"2972_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372:232\u2013240","journal-title":"N Engl J Med"},{"key":"2972_CR36","doi-asserted-by":"crossref","unstructured":"Willmann S, Marostica E, Snelder N, Solms A, Jensen M, Lobmeyer M, Lensing AW, Bethune C, Morgan E, Yu RZ (2021) PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose\u2010FXI activity relation from healthy volunteers to end\u2010stage renal disease patients. CPT: Pharmacometrics Syst Pharmacol 10:890\u2013901","DOI":"10.1002\/psp4.12663"},{"key":"2972_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jth.15588","volume":"20","author":"PC Wong","year":"2022","unstructured":"Wong PC, Crain EJ, Bozarth JM, Wu Y, Dilger AK, Wexler RR, Ewing WR, Gordon D, Luettgen JM (2022) Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits. J Thromb Haemost 20:399\u2013408","journal-title":"J Thromb Haemost"},{"key":"2972_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A et al (2024) Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 23:46\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(23)00403-9","journal-title":"Lancet Neurol"},{"key":"2972_CR39","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/jth.15700","volume":"20","author":"S Heitmeier","year":"2022","unstructured":"Heitmeier S, Visser M, Tersteegen A, Dietze-Torres J, Glunz J, Gerdes C, Laux V, Stampfuss J, Roehrig S (2022) Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost 20:1400\u20131411","journal-title":"J Thromb Haemost"},{"key":"2972_CR40","doi-asserted-by":"publisher","first-page":"e0196","DOI":"10.1097\/CCE.0000000000000196","volume":"2","author":"CV Pollack Jr","year":"2020","unstructured":"Pollack CV Jr, Kurz MA, Hayward NJ (2020) EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: a brief report. Crit Care Explor 2:e0196","journal-title":"Crit Care Explor"},{"key":"2972_CR41","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1111\/bcp.14732","volume":"87","author":"D Beale","year":"2021","unstructured":"Beale D, Dennison J, Boyce M, Mazzo F, Honda N, Smith P, Bruce M (2021) ONO-7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study. Br J Clin Pharmacol 87:3177\u20133189","journal-title":"Br J Clin Pharmacol"},{"key":"2972_CR42","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bcp.13520","volume":"84","author":"V Perera","year":"2018","unstructured":"Perera V, Luettgen JM, Wang Z, Frost CE, Yones C, Russo C, Lee J, Zhao Y, LaCreta FP, Ma X (2018) First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. Br J Clin Pharmacol 84:876\u2013887","journal-title":"Br J Clin Pharmacol"},{"key":"2972_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/13543776.2020.1705783","volume":"30","author":"RA Al-Horani","year":"2020","unstructured":"Al-Horani RA, Factor XI (2020) a) inhibitors for thrombosis: an updated patent review (2016-present). Expert Opin Ther Pat 30:39\u201355","journal-title":"Expert Opin Ther Pat"},{"key":"2972_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/ATVBAHA.119.312459","volume":"39","author":"NC Chan","year":"2019","unstructured":"Chan NC, Weitz JI (2019) AB023, a novel antibody that binds factor XI and blocks its activation by factor XIIa. Arterioscler Thromb Vasc Biol 39:533\u2013535. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312459","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2972_CR45","doi-asserted-by":"crossref","unstructured":"Tabrizi MA, Tseng C-ML, Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81\u201388","DOI":"10.1016\/S1359-6446(05)03638-X"},{"key":"2972_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/FJC.0000000000000921","volume":"76","author":"CJ Beavers","year":"2020","unstructured":"Beavers CJ, Wayne NB (2020) Osocimab: a novel agent in preventing venous thromboembolism. J Cardiovasc Pharmacol 76:645\u2013649","journal-title":"J Cardiovasc Pharmacol"},{"key":"2972_CR47","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","volume":"113","author":"EI Tucker","year":"2009","unstructured":"Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJ, Gailani D, Gruber A, Hanson SR (2009) Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 113:936\u2013944","journal-title":"Blood"},{"key":"2972_CR48","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","volume":"66","author":"Z Xie","year":"2023","unstructured":"Xie Z, Meng Z, Yang X, Duan Y, Wang Q, Liao C (2023) Factor XIa inhibitors in anticoagulation therapy: recent advances and perspectives. J Med Chem 66:5332\u20135363","journal-title":"J Med Chem"},{"key":"2972_CR49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jth.12797","volume":"13","author":"W Chen","year":"2015","unstructured":"Chen W, Carvalho L, Chan M, Kini R, Kang T (2015) Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity. J Thromb Haemost 13:248\u2013261","journal-title":"J Thromb Haemost"},{"key":"2972_CR50","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1084\/jem.20091007","volume":"206","author":"Y Decrem","year":"2009","unstructured":"Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J, Fr\u00e8re J-M, Feron O, Dogn\u00e9 J-M, Dessy C (2009) Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 206:2381\u20132395","journal-title":"J Exp Med"},{"key":"2972_CR51","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood-2013-08-517474","volume":"122","author":"D Ma","year":"2013","unstructured":"Ma D, Mizurini DM, Assump\u00e7\u00e3o TC, Li Y, Qi Y, Kotsyfakis M, Ribeiro JM, Monteiro RQ, Francischetti IM (2013) Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo. Blood 122:4094\u20134106","journal-title":"Blood"},{"key":"2972_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bbrc.2009.12.177","volume":"392","author":"D Li","year":"2010","unstructured":"Li D, He Q, Kang T, Yin H, Jin X, Li H, Gan W, Yang C, Hu J, Wu Y (2010) Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa\/tissue factor from the blood-feeding nematode Ancylostoma caninum. Biochem Biophys Res Commun 392:155\u2013159","journal-title":"Biochem Biophys Res Commun"},{"key":"2972_CR53","doi-asserted-by":"publisher","first-page":"e0004298","DOI":"10.1371\/journal.pntd.0004298","volume":"10","author":"TC Assumpcao","year":"2016","unstructured":"Assumpcao TC, Ma D, Mizurini DM, Kini RM, Ribeiro JM, Kotsyfakis M, Monteiro RQ, Francischetti IM (2016) In vitro mode of action and anti-thrombotic activity of boophilin, a multifunctional Kunitz protease inhibitor from the midgut of a tick vector of babesiosis, Rhipicephalus microplus. PLoS Negl Trop Dis 10:e0004298","journal-title":"PLoS Negl Trop Dis"},{"key":"2972_CR54","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41598-017-02055-x","volume":"7","author":"DA Donkor","year":"2017","unstructured":"Donkor DA, Bhakta V, Eltringham-Smith LJ, Stafford AR, Weitz JI, Sheffield WP (2017) Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep 7:2102","journal-title":"Sci Rep"},{"key":"2972_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/blood.V68.1.225.225","volume":"68","author":"PN Walsh","year":"1986","unstructured":"Walsh PN, Sinha D, Koshy A, Seaman FS, Bradford H (1986) Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface. Blood 68:225\u2013230","journal-title":"Blood"},{"key":"2972_CR56","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR Buller","year":"2015","unstructured":"Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372:232\u2013240. https:\/\/doi.org\/10.1056\/NEJMoa1405760","journal-title":"N Engl J Med"},{"key":"2972_CR57","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A (2021) Milvexian for the prevention of venous thromboembolism. N Engl J Med 385:2161\u20132172","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02972-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02972-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02972-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T18:03:43Z","timestamp":1734113023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02972-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02972-5","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"19 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}